Advance of Serum Biomarkers and Combined Diagnostic Panels in Nonalcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease (NAFLD) affects approximately 25-30% population worldwide, which progresses from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma, and has complications such as cardiovascular events. Liver biopsy is still the...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Yuping, He, He, An, Zhenmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259243/
https://www.ncbi.nlm.nih.gov/pubmed/35811662
http://dx.doi.org/10.1155/2022/1254014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259243/
https://www.ncbi.nlm.nih.gov/pubmed/35811662
http://dx.doi.org/10.1155/2022/1254014

Ejemplares similares